<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981240</url>
  </required_header>
  <id_info>
    <org_study_id>TED10416</org_study_id>
    <nct_id>NCT00981240</nct_id>
  </id_info>
  <brief_title>Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes</brief_title>
  <official_title>A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objectives:&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose&#xD;
           limiting toxicities (DLTs) in the proposed dose regimen&#xD;
&#xD;
        -  To evaluate the pharmacokinetic (PK) profile of SAR103168&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To characterize the global safety profile of SAR103168&#xD;
&#xD;
        -  To evaluate preliminary anti-leukemia activity&#xD;
&#xD;
        -  To investigate the potential induction effect on CYP3A4 and persistence of this effect&#xD;
           by using oral midazolam as a probe substrate in patients enrolled into the expanded&#xD;
           cohort at the MTD&#xD;
&#xD;
        -  To determine the metabolic pathways of SAR103168 and identify the chemical structures of&#xD;
           metabolites&#xD;
&#xD;
        -  To determine the potential impact of SAR103168 on the QTc interval in patients enrolled&#xD;
           at the MTD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive the study drug until unacceptable toxicity, clinically significant&#xD;
      disease progression, withdrawal of consent or investigator's decision, and for a maximum of 1&#xD;
      year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DLTs during the initial 4-week period of treatment</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of SAR103168</measure>
    <time_frame>First course: Days 1, 2, 5, 6, and 8; Second and subsequent courses: Day 5 only</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global safety profile of SAR103168 based on treatment emergent adverse events (TEAEs), serious adverse events (SAEs), deaths, laboratory abnormalities</measure>
    <time_frame>Treatment period up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary evidence of anti-leukemia activity</measure>
    <time_frame>Treatment period up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of midazolam in the absence and the presence of SAR103168.</measure>
    <time_frame>During second (Day-1 and Day 5) and forth course (Day 5)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR103168</intervention_name>
    <description>Pharmaceutical form: Concentrate for solution for infusion&#xD;
Route of administration: Intravenous infusion</description>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with refractory/relapsed acute leukemias or high-risk myelodysplastic&#xD;
             syndromes with no curative option available including any of the following:&#xD;
&#xD;
               -  Patients with de novo or secondary acute myelogenous leukemia (AML) (except acute&#xD;
                  promyelocytic leukemia), meeting one of the following conditions:&#xD;
&#xD;
               -  Refractory or relapsed AML; In case of first relapse the CR duration should be&#xD;
                  less than 12 months. If the relapse failed at least one prior salvage attempt,&#xD;
                  the CR duration may be more than 12 months.&#xD;
&#xD;
               -  Into the expanded cohort at the MTD, previously untreated AML patients over age&#xD;
                  60 with poor- risk cytogenetics who are not eligible for or do not accept&#xD;
                  induction chemotherapy may also be included.&#xD;
&#xD;
          -  Patients with refractory/relapsed acute lymphoblastic leukemia (ALL)&#xD;
&#xD;
          -  Patients with high-risk myelodysplastic syndrome (MDS) as defined by the International&#xD;
             Prognostic Scoring System&#xD;
&#xD;
          -  Patients with chronic myeloid leukemia in blast phase (CML-BP)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  performance status &gt; 2&#xD;
&#xD;
          -  Active uncontrolled central nervous system leukemia&#xD;
&#xD;
          -  Cytotoxic therapy within 2 weeks prior to the first dose of SAR103168. For the non&#xD;
             cytotoxic agents/investigational drugs this washout period should be at least 2 weeks&#xD;
             or at least 5 half-lives whichever is longer. Hydroxyurea must be stopped at least 24&#xD;
             hours prior to the first dose of SAR103168&#xD;
&#xD;
          -  Lack of recovery from toxicities from prior therapies to grade &lt; 1&#xD;
&#xD;
          -  White blood cells &gt; 30 x 10^9/L prior to the first dose of SAR103168&#xD;
&#xD;
          -  Prior allogeneic stem cell transplantation or donor lymphocytes infusion within 3&#xD;
             months preceding the first dose of SAR103168&#xD;
&#xD;
          -  Any of the following within 6 months prior to the first dose of SAR103168:&#xD;
&#xD;
               -  Myocardial infarction, congestive heart failure, documented angina pectoris,&#xD;
                  arrhythmia requiring medication (in particular atrial fibrillation or flutter),&#xD;
                  severe conduction disorder (second or third atrio-ventricular block, pacemaker),&#xD;
                  coronary/peripheral artery bypass graft surgery&#xD;
&#xD;
               -  Arterial or venous thromboembolism, deep venous thrombosis&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50% by echocardiography or multiple gated&#xD;
             acquisition scan&#xD;
&#xD;
          -  Cardiac ischemia on 12-lead ECG&#xD;
&#xD;
          -  Baseline QTc-interval &gt; 500 msec&#xD;
&#xD;
          -  Hypertension uncontrolled with appropriate therapy&#xD;
&#xD;
          -  Active infection (viral, bacterial or fungal) uncontrolled with appropriate therapy&#xD;
&#xD;
          -  Major surgery within 6 weeks prior to the first dose of SAR103168&#xD;
&#xD;
          -  Poor organ function defined by one of the following:&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 x upper limit of normal (ULN) unless related to leukemia&#xD;
                  (i.e. hemolysis) or Gilbert's syndrome&#xD;
&#xD;
               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) &gt; 2.5 x ULN&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5 x ULN or calculated creatinine clearance &lt; 50 mL/min&#xD;
&#xD;
          -  Patients under treatment with potent inhibitors of CYP3A4 unless these treatments may&#xD;
             be stopped at least 3 days prior to the first dose of SAR103168&#xD;
&#xD;
          -  Patients under treatment with CYP3A4 or CYP2C9 inducers, unless these treatments may&#xD;
             be stopped at least 3 days prior to the first dose of SAR103168&#xD;
&#xD;
          -  Pregnant or breast-feeding women or refusal to use adequate contraceptive method, when&#xD;
             applicable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Ravandi-Kashani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center, Houston, Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840003</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840002</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 840001</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

